Contamination Control in Pharmaceutical Industries
Pharmaceutical manufacturing facilities operate under some of the world's most stringent contamination control requirements, where product quality, patient safety, and regulatory compliance depend on the implementation of effective preventive measures.
The latest EU GMP Annex 1 places particular emphasis on the adoption of a comprehensive Contamination Control Strategy (CCS), requiring manufacturers to identify potential contamination sources and implement preventive controls throughout facilities, equipment, personnel, and manufacturing processes. Rather than simply removing contamination after it occurs, pharmaceutical companies are expected to minimize contamination risks at every stage of production.
Microbiological contamination, particulate matter, and cross-contamination can compromise product integrity and lead to significant operational and regulatory consequences. For this reason, contamination control must begin before contaminants reach critical manufacturing environments, supporting both product protection and compliance with GMP requirements.
Consequences of Contamination:
Risks to
patient safety
Damage to brand reputation
Product recalls
Compromised process reliability
Batch rejection and material waste
Legal and financial penalties
Production
downtime
Regulatory
non-compliance
The role of Floors in Contamination Control
Personnel remain one of the primary sources of contamination within pharmaceutical facilities. Every movement of operators, carts, material transfer systems, and mobile equipment contributes to the introduction and redistribution of contaminants throughout controlled environments.
Although floors are not product-contact surfaces, they represent one of the main routes through which contaminants are introduced and transferred between manufacturing areas. Footwear and wheels can transport particulate matter and microorganisms across different hygiene zones, increasing the risk of contamination spreading throughout the facility.
The preventive approach promoted by the EU GMP Annex 1 recognizes that contamination control must consider all potential contamination pathways. Flooring therefore plays an important role in supporting an effective Contamination Control Strategy by helping to minimize contamination transfer at critical access points.
Lower-Risk Area
Movement
Contamination accumulate on the floor
People, carts and material move between areas
Sensitive area
Contaminants can be transferred into high-care areas
Washable Contamination Control Mats:
an additional Barrier against Contamination
Our washable decontamination mats provide an effective preventive solution for contamination control in pharmaceutical manufacturing facilities by helping to reduce the introduction and transfer of contaminants carried by shoes and wheels before they can spread throughout production environments.
Designed for continuous use in demanding industrial environments, our mats combine durability, hygiene, and ease of maintenance. Their washable surface allows them to be repeatedly cleaned and sanitized without compromising performance, making them particularly suitable for facilities operating under strict hygiene protocols.
The material features antibacterial properties tested according to ISO 22196:2011 through the use of silver ion technology integrated into the PVC matrix, contributing to the reduction of bacterial contamination on the mat surface.
Our mats are also:
- resistant to almost all chemical cleaning and sanitizing agents used in food manufacturing facilities;
- suitable for operating temperatures ranging from -15 °C to +100 °C (short-term exposure), allowing their use in both refrigerated and high-temperature production environments;
- available in different colors for visual zoning and hygiene area management;
- fully washable and designed for continuous use in high-traffic production environments.
By helping to reduce contamination transfer at critical access points, our mats complement GMP-compliant contamination control strategies and support the preventive approach promoted by the EU GMP Annex 1.
They represent the first preventive barrier against contamination transfer, helping pharmaceutical manufacturers protect product quality and maintain regulatory compliance throughout the manufacturing process.
